CKClaus Kremoser

Claus Kremoser

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Claus Kremoser has a total of 40 co-authors. Here are the top co-authors by number of shared publications:

  • Eva Hambruch

    Phenex Pharmaceuticals AG, Drug Discovery Research, Heidelberg, Germany

    2 shared publications
  • Olaf Kinzel

    Phenex Pharmaceuticals AG, Drug Discovery Research, Heidelberg, Germany

    2 shared publications
  • Ulrich Deuschle

    Phenex Pharmaceuticals AG, Heidelberg, Germany (E.H., S.P.-O., T.S., O.K., H.D.K., U.D., C.K.); Division of Renal Diseases and Hypertension, University of Colorado, Denver, Colorado (S.M.-A., M.L., M.M.); Synovo GmbH, Tübingen, Germany (U.H., M.B.); and Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany (S.M., A.B., G.S.)

    2 shared publications
  • Alfred Boettcher

    Phenex Pharmaceuticals AG, Heidelberg, Germany (E.H., S.P.-O., T.S., O.K., H.D.K., U.D., C.K.); Division of Renal Diseases and Hypertension, University of Colorado, Denver, Colorado (S.M.-A., M.L., M.M.); Synovo GmbH, Tübingen, Germany (U.H., M.B.); and Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany (S.M., A.B., G.S.)

    1 shared publication
  • C. Gege

    Phenex Pharmaceut AG, Heidelberg, Germany

    1 shared publication
  • Christian Gege

    Innovative Molecules GmbH

    1 shared publication

Latest Publications

  • Open Access

    The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model

    by Philipp Schwabl, Eva Hambruch, Grant R. Budas, Paul Supper, Michael Burnet, John T. Liles, Manfred Birkel, Ksenia Brusilovskaya, Philipp Königshofer, Markus Peck-Radosavljevic, et al.

    Background: The farnesoid X receptor (FXR) influences hepatic metabolism, inflammation and liver fibrosis as key components of non-alcoholic steatohepatitis (NASH). We studied the effects of the non-steroidal FXR agonist cilofexor (formerly GS-9674) on portal pressure and fibrosis in experimental NASH. Methods: NASH was induced in Wistar rats using a choline-deficient high-fat diet plus intraperitoneal sodium nitrite injections. First, a dose-finding study was performed with 10 mg/kg and 30 mg/kg of cilofexor, focusing on histological readouts. Liver fibrosis was assessed by Picro-Sirius-Red, desmin staining and hepatic hydroxyproline content. Gene expression was determined by RT-PCR. In a subsequent hemodynamic study, rats received 30 mg/kg cilofexor with or without propranolol (25 mg/kg). Portal pressure, systemic hemodynamics and splanchnic blood flow were measured. Results: Cilofexor dose-dependently induced FXR target genes shp, cyp7a1 and fgf15 in hepatic and ileal tissues, paralleled by a dose-dependent reduction in liver fibrosis area (Picro-Sirius-Red) of −41% (10 mg/kg) and −69% (30 mg/kg), respectively. The 30 mg/kg cilofexor dose significantly reduced hepatic hydroxyproline content (−41%), expression of col1a1 (−37%) and pdgfr-β (−36%), as well as desmin area (−42%) in NASH rats. Importantly, cilofexor decreased portal pressure (11.9 ± 2.1 vs. 8.9 ± 2.2 mmHg; p = 0.020) without affecting splanchnic blood-flow or systemic hemodynamics. The addition of propranolol to cilofexor additionally reduced splanchnic inflow (−28%) but also mean arterial pressure (−25%) and heart rate (−37%). Conclusion: The non-steroidal FXR agonist cilofexor decreased portal hypertension and reduced liver fibrosis in NASH rats. While cilofexor seems to primarily decrease sinusoidal resistance in cirrhotic portal hypertension, the combination with propranolol additionally reduced mesenteric hyperperfusion.


  • Nonsteroidal FXR Ligands: Current Status and Clinical Applications

    by Christian Gege, Eva Hambruch, Nina Hambruch, Olaf Kinzel, Claus Kremoser

    FXR agonists have demonstrated very promising clinical results in the treatment of liver disorders such as primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH). NASH, in particular, is one of the last uncharted white territories in the pharma landscape, and there is a huge medical need and a large potential pharmaceutical market for a NASH pharmacotherapy. Clinical efficacy superior to most other treatment options was shown by FXR agonists such as obeticholic acid (OCA) as they improved various metabolic features including liver steatosis as well as liver inflammation and fibrosis. But OCA’s clinical success comes with some major liabilities such as pruritus, high-density lipoprotein cholesterol (HDLc) lowering, low-density lipoprotein cholesterol (LDLc) increase, and a potential for drug-induced liver toxicity. Some of these effects can be attributed to on-target effects exerted by FXR, but with others it is not clear whether it is FXR- or OCA-related. Therefore a quest for novel, proprietary FXR agonists is ongoing with the aim to increase FXR potency and selectivity over other proteins and to overcome at least some of the OCA-associated clinical side effects through an improved pharmacology. In this chapter we will discuss the historical and ongoing efforts in the identification and development of nonsteroidal, which largely means non-bile acid-type, FXR agonists for clinical use.


  • LXR inverse agonists inhibit de novo lipogenesis and reduce intestinal lipid and cholesterol absorption in a NAFLD mouse model

    by C. Kremoser, U. Deuschle, C. Gege, O. Kinzel, H.D. Krol, M. Albers, M. Birkel, E. Hambruch

  • Synthetic Farnesoid X Receptor Agonists Induce High-Density Lipoprotein-Mediated Transhepatic Cholesterol Efflux in Mice and Monkeys and Prevent Atherosclerosis in Cholesteryl Ester Transfer Protein Transgenic Low-Density Lipoprotein Receptor (−/−) Mice

    by Eva Hambruch, Shinobu Miyazaki-Anzai, Ulrike Hahn, Silke Matysik, Alfred Boettcher, Sanja Perović-Ottstadt, Thomas Schlüter, Olaf Kinzel, Helen Desiree Krol, Ulrich Deuschle, et al.

    Farnesoid X receptor (FXR), a bile acid-activated nuclear hormone receptor, plays an important role in the regulation of cholesterol and more specifically high-density lipoprotein (HDL) homeostasis. Activation of FXR is reported to lead to both pro- and anti-atherosclerotic effects. In the present study we analyzed the impact of different FXR agonists on cholesterol homeostasis, plasma lipoprotein profiles, and transhepatic cholesterol efflux in C57BL/6J mice and cynomolgus monkeys and atherosclerosis development in cholesteryl ester transfer protein transgenic (CETPtg) low-density lipoprotein receptor (LDLR) (−/−) mice. In C57BL/6J mice on a high-fat diet the synthetic FXR agonists isopropyl 3-(3,4-difluorobenzoyl)-1,1-dimethyl-1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate (FXR-450) and 4-[2-[2-chloro-4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-4-isoxazolyl]methoxy]phenyl]cyclopropyl]benzoic acid (PX20606) demonstrated potent plasma cholesterol-lowering activity that affected all lipoprotein species, whereas 3-[2-[2-chloro-4-[[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methoxy]phenyl]ethenyl]benzoic acid (GW4064) and 6-ethyl chenodeoxycholic acid (6-ECDCA) showed only limited effects. In FXR wild-type mice, but not FXR(−/−) mice, the more efficacious FXR agonists increased fecal cholesterol excretion and reduced intestinal cholesterol (re)uptake. In CETPtg-LDLR(−/−) mice PX20606 potently lowered total cholesterol and, despite the observed HDL cholesterol (HDLc) reduction, caused a highly significant decrease in atherosclerotic plaque size. In normolipidemic cynomolgus monkeys PX20606 and 6-ECDCA both reduced total cholesterol, and PX20606 specifically lowered HDL2c but not HDL3c or apolipoprotein A1. That pharmacological FXR activation specifically affects this cholesterol-rich HDL2 subclass is a new and highly interesting finding and sheds new light on FXR-dependent HDLc lowering, which has been perceived as a major limitation for the clinical development of FXR agonists.


  • Panning for SNuRMs: using cofactor profiling for the rational discovery of selective nuclear receptor modulators

    by Claus Kremoser, Michael Albers, Thomas P. Burris, Ulrich Deuschle, Manfred Koegl